(1R,2R)-N-(1-cyanocyclopropyl)-2-(1,3-dihydro-2H-isoindol-2-ylcarbonyl)cyclohexanecarboxamide | 1095715-69-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: (1R,2R)-N-(1-cyanocyclopropyl)-2-(1,3-dihydro-2H-isoindol-2-ylcarbonyl)cyclohexanecarboxamide
• 英文别名: (1R,2R)-N-(1-cyanocyclopropyl)-2-(1,3-dihydroisoindole-2-carbonyl)cyclohexane-1-carboxamide
• CAS: 1095715-69-7
• 化学式: C₂₀H₂₃N₃O₂
• 分子量: 337.422
• InChiKey: ZLXWTSUVDRTIPA-IAGOWNOFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  73.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  异吲哚啉 、 反式-1,2-环己二羧酸酐 、 1-氨基-1-环丙基腈盐酸盐 在 N,N-二异丙基乙胺 、 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 以38%的产率得到(1R,2R)-N-(1-cyanocyclopropyl)-2-(1,3-dihydro-2H-isoindol-2-ylcarbonyl)cyclohexanecarboxamide
  参考文献：
  名称：

  Pharmacokinetic Benefits of 3,4-Dimethoxy Substitution of a Phenyl Ring and Design of Isosteres Yielding Orally Available Cathepsin K Inhibitors

  摘要：

  Rational structure-based design has yielded highly potent inhibitors of cathepsin K (Cat K) with excellent physical properties, selectivity profiles, and pharmacokinetics. Compounds with a 3,4-(CH3O)(2)Ph motif, such as 31, were found to have excellent metabolic stability and absorption profiles. Through metabolite identification studies, a reactive metabolite risk was identified with this motif: Subsequent structure-based design of isoteres culminated in the discovery of an optimized and balanced inhibitor (indazole, 38).

  DOI：

  10.1021/jm301119s

文献信息

• [EN] 1,2-CYCL0HEXANE DICARBOXAMIDES AS CATHEPSIN INHIBITORS<br/>[FR] 1,2-CYCLOHEXANE DICARBOXAMIDES UTILISÉS COMME INHIBITEURS DES CATHEPSINES
  申请人：ASTRAZENECA AB

  公开号：WO2009001128A1

  公开（公告）日：2008-12-31

  [EN] The present invention relates to compounds and compositions for treating diseases associated with cysteine protease activity. The compounds are reversible inhibitors of cysteine proteases, including cathepsins B, K, C, F, H, L, O, S, W and X. Of particular interest are diseases associated with Cathepsin K.
  [FR] L'invention concerne des composés et des compositions destinés au traitement de maladies associées à l'activité cystéine protéase. Les composés de l'invention sont des inhibiteurs réversibles des cystéine protéases, entre autres les cathepsines B, K, C, F, H, L, O, S, W et X. L'invention offre un intérêt particulier pour les maladies associées à la cathepsine K. Formule (I):
• Pharmacokinetic Benefits of 3,4-Dimethoxy Substitution of a Phenyl Ring and Design of Isosteres Yielding Orally Available Cathepsin K Inhibitors
  作者：James J. Crawford、Peter W. Kenny、Jonathan Bowyer、Calum R. Cook、Jonathan E. Finlayson、Christine Heyes、Adrian J. Highton、Julian A. Hudson、Anja Jestel、Stephan Krapp、Scott Martin、Philip A. MacFaul、Benjamin P. McDermott、Thomas M. McGuire、Andrew D. Morley、Jeffrey J. Morris、Ken M. Page、Lyn Rosenbrier Ribeiro、Helen Sawney、Stefan Steinbacher、Caroline Smith、Alexander G. Dossetter

  DOI：10.1021/jm301119s

  日期：2012.10.25

  Rational structure-based design has yielded highly potent inhibitors of cathepsin K (Cat K) with excellent physical properties, selectivity profiles, and pharmacokinetics. Compounds with a 3,4-(CH3O)(2)Ph motif, such as 31, were found to have excellent metabolic stability and absorption profiles. Through metabolite identification studies, a reactive metabolite risk was identified with this motif: Subsequent structure-based design of isoteres culminated in the discovery of an optimized and balanced inhibitor (indazole, 38).